Abstract
Purpose: The purpose of this study was to use optical coherence tomography angiography (OCTA) to compare the morphology characteristics of type 1 and 2 choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD) patients. Materials and Methods: This is a retrospective, observational study of 51 eyes with nAMD using OCTA from July 2016 through March 2017. Results: In total, 51 eyes of 50 patients were included in the analysis. According to the anatomical classification based on OCT, 27 eyes (53%) were diagnosed with type 1 CNV, and 24 eyes (47%) were type 2 CNV. Type 2 CNV was characterized by smaller flow area, smaller greatest vascular caliber (GVC), smaller greatest linear dimension (GLD), and shorter duration of disease. The duration of disease only correlated with GVC (p = 0.026) in multivariate linear regression results. Meanwhile, GLD correlated with GVC and flow area whereas GVC was not associated with flow area. Conclusion: This study demonstrated that type 2 CNV was characterized by shorter duration of disease, smaller GVC, smaller GLD, and smaller flow area compared with type 1 CNV. Additionally, we showed that the duration of the disease correlated with GVC of the CNV.
References
1.
Resnikoff
S
, Pascolini
D
, Etya’ale
D
, Kocur
I
, Pararajasegaram
R
, Pokharel
GP
, et al Global data on visual impairment in the year 2002
. Bull World Health Organ
. 2004
Nov
;82
(11
):844
–51
.
[PubMed]
0042-96862.
Martin
DF
, Maguire
MG
, Ying
GS
, Grunwald
JE
, Fine
SL
, Jaffe
GJ
; CATT Research Group
. Ranibizumab and bevacizumab for neovascular age-related macular degeneration
. N Engl J Med
. 2011
May
;364
(20
):1897
–908
.
[PubMed]
0028-47933.
Rosenfeld
PJ
, Brown
DM
, Heier
JS
, Boyer
DS
, Kaiser
PK
, Chung
CY
, et al; MARINA Study Group
. Ranibizumab for neovascular age-related macular degeneration
. N Engl J Med
. 2006
Oct
;355
(14
):1419
–31
.
[PubMed]
0028-47934.
Heier
JS
, Brown
DM
, Chong
V
, Korobelnik
JF
, Kaiser
PK
, Nguyen
QD
, et al; VIEW 1 and VIEW 2 Study Groups
. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
. Ophthalmology
. 2012
Dec
;119
(12
):2537
–48
.
[PubMed]
0161-64205.
Zarranz-Ventura
J
, Liew
G
, Johnston
RL
, Xing
W
, Akerele
T
, McKibbin
M
, et al; United Kingdom Age-Related Macular Degeneration Electronic Medical Records Users Group
. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes
. Ophthalmology
. 2014
Oct
;121
(10
):1966
–75
.
[PubMed]
0161-64206.
Jaffe
GJ
, Martin
DF
, Toth
CA
, Daniel
E
, Maguire
MG
, Ying
GS
, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
. Ophthalmology
. 2013
Sep
;120
(9
):1860
–70
.
[PubMed]
0161-64207.
Kitchens
JW
, Kassem
N
, Wood
W
, Stone
TW
, Isernhagen
R
, Wood
E
, et al A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
. Clin Ophthalmol
. 2013
;7
:1987
–93
.
[PubMed]
1177-54678.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity
. Ophthalmology
. 2014
May
;121
(5
):1092
–101
.
[PubMed]
0161-64209.
Gharbiya
M
, Giustolisi
R
, Marchiori
J
, Bruscolini
A
, Mallone
F
, Fameli
V
, et al Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes
. Curr Eye Res
. 2018
Mar
;43
(3
):391
–6
.
[PubMed]
0271-368310.
Lee
JY
, Chung
H
, Kim
HC
. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration
. Korean J Ophthalmol
. 2016
Feb
;30
(1
):17
–24
.
[PubMed]
1011-894211.
Casalino
G
, Bandello
F
, Chakravarthy
U
. Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF Treatment in Age-Related Macular Degeneration: An Integrated Multimodal Imaging Analysis
. Invest Ophthalmol Vis Sci
. 2016
Jul
;57
(9
):OCT288
–98
.
[PubMed]
0146-040412.
Gass
JD
. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes
. Am J Ophthalmol
. 1994
Sep
;118
(3
):285
–98
.
[PubMed]
0002-939413.
Spaide
RF
, Klancnik
JM
Jr, Cooney
MJ
. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography
. JAMA Ophthalmol
. 2015
Jan
;133
(1
):45
–50
.
[PubMed]
2168-616514.
Farecki
ML
, Gutfleisch
M
, Faatz
H
, Rothaus
K
, Heimes
B
, Spital
G
, et al Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography
. Graefes Arch Clin Exp Ophthalmol
. 2017
May
;255
(5
):913
–21
.
[PubMed]
0721-832X15.
Phasukkijwatana
N
, Tan
AC
, Chen
X
, Freund
KB
, Sarraf
D
. Optical coherence tomography angiography of type 3 neovascularisation in age-related macular degeneration after antiangiogenic therapy
. Br J Ophthalmol
. 2017
May
;101
(5
):597
–602
.
[PubMed]
0007-116116.
Muakkassa
NW
, Chin
AT
, de Carlo
T
, Klein
KA
, Baumal
CR
, Witkin
AJ
, et al CHARACTERIZING THE EFFECT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ON TREATMENT-NAIVE CHOROIDAL NEOVASCULARIZATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
. Retina
. 2015
Nov
;35
(11
):2252
–9
.
[PubMed]
0275-004X17.
Kuehlewein
L
, Bansal
M
, Lenis
TL
, Iafe
NA
, Sadda
SR
, Bonini Filho
MA
, et al Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration
. Am J Ophthalmol
. 2015
Oct
;160
(4
):739
–48.e2
.
[PubMed]
0002-939418.
El Ameen
A
, Cohen
SY
, Semoun
O
, Miere
A
, Srour
M
, Quaranta-El Maftouhi
M
, et al Type 2 neovascularization secondary to age-related macular degeneration imaged by optical coherence tomography angiography
. Retina
. 2015
Nov
;35
(11
):2212
–8
.
[PubMed]
0275-004X19.
Miere
A
, Semoun
O
, Cohen
SY
, El Ameen
A
, Srour
M
, Jung
C
, et al OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF SUBRETINAL FIBROSIS IN AGE-RELATED MACULAR DEGENERATION
. Retina
. 2015
Nov
;35
(11
):2275
–84
.
[PubMed]
0275-004X20.
Wirth
MA
, Freiberg
F
, Pfau
M
, Wons
J
, Becker
MD
, Michels
S
. Optical coherence tomography angiography in age-related macular degeneration: persistence of vascular network in quiescent choroidal neovascularization
. Acta Ophthalmol
. 2016
Sep
;•••
:
[PubMed]
1755-375X21.
Lumbroso
B
, Rispoli
M
, Savastano
MC
. LONGITUDINAL OPTICAL COHERENCE TOMOGRAPHY-ANGIOGRAPHY STUDY OF TYPE 2 NAIVE CHOROIDAL NEOVASCULARIZATION EARLY RESPONSE AFTER TREATMENT
. Retina
. 2015
Nov
;35
(11
):2242
–51
.
[PubMed]
0275-004X22.
Gong
J
, Yu
S
, Gong
Y
, Wang
F
, Sun
X
. The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography
. J Ophthalmol
. 2016
;2016
:7521478
.
[PubMed]
2090-004X23.
Chen
X
, Al-Sheikh
M
, Chan
CK
, Hariri
AH
, Abraham
P
, Lalezary
M
, et al TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study
. Retina
. 2016
Dec
;36
Suppl 1
:S50
–64
.
[PubMed]
0275-004X24.
Boyer
DS
, Antoszyk
AN
, Awh
CC
, Bhisitkul
RB
, Shapiro
H
, Acharya
NR
; MARINA Study Group
. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration
. Ophthalmology
. 2007
Feb
;114
(2
):246
–52
.
[PubMed]
0161-642025.
Ying
GS
, Huang
J
, Maguire
MG
, Jaffe
GJ
, Grunwald
JE
, Toth
C
, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
. Ophthalmology
. 2013
Jan
;120
(1
):122
–9
.
[PubMed]
0161-642026.
Lee
JE
, Kim
HW
, Lee
SJ
, Lee
JE
. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection
. Retina
. 2015
May
;35
(5
):999
–1006
.
[PubMed]
0275-004X27.
Freund
KB
, Zweifel
SA
, Engelbert
M
. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?
Retina
. 2010
Oct
;30
(9
):1333
–49
.
[PubMed]
0275-004X28.
Spaide
RF
. Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization
. Am J Ophthalmol
. 2015
Jul
;160
(1
):6
–16
.
[PubMed]
0002-939429.
Shiraga
F
, Ojima
Y
, Matsuo
T
, Takasu
I
, Matsuo
N
. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration
. Ophthalmology
. 1998
Apr
;105
(4
):662
–9
.
[PubMed]
0161-642030.
Piermarocchi
S
, Lo Giudice
G
, Sartore
M
, Friede
F
, Segato
T
, Pilotto
E
, et al Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration
. Am J Ophthalmol
. 2002
Apr
;133
(4
):572
–5
.
[PubMed]
0002-939431.
Helfrich
I
, Scheffrahn
I
, Bartling
S
, Weis
J
, von Felbert
V
, Middleton
M
, et al Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
. J Exp Med
. 2010
Mar
;207
(3
):491
–503
.
[PubMed]
0022-100732.
Wietecha
MS
, Cerny
WL
, DiPietro
LA
. Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis
. Curr Top Microbiol Immunol
. 2013
;367
:3
–32
.
[PubMed]
0070-217X© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
